Perrigo Company Plc, the Irish-based generic drugmaker trying to fend off a hostile bid by Mylan NV, held unsuccessful talks to acquire Endo International Plc in an all-stock deal, according to people familiar with the matter.
The negotiations show how Perrigo has been on the M&A prowl seeking to present its shareholders with an alternative to a deal with Mylan, as well as its willingness to walk away if it cannot reach terms that it considers to be attractive.
The talks earlier this fall, first reported on by the Wall Street Journal, were advanced enough for major issues such as the role of Endo’s chief executive Rajiv De Silva and how the companies could be integrated to have been addressed, the people said on Thursday.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Read the full story at Reuters, by Greg Roumeliotis and Carl O’donnell
READ MORE: MYLAN, PERRIGO
Under the settlement agreement with the Federal Trade Commission, subject to final approval, Mylan NV has agreed to sell the rights and assets related to seven generic drugs to secure regulatory approval of More…
Shares in the U.S. generic drugmaker Mylan will begin trading on the Tel Aviv Stock Exchange Wednesday, the TASE said Monday. The move comes after Mylan last week won an Israeli court ruling rejecting Perrigo’s More…
Mylan N.V., which made a hostile takeover bid for Perrigo Co., said Friday that a U.S. District court denied Perrigo’s attempt to block the potential closing of Mylan’s proposed offer before shareholders. The More…
Perrigo, which is the target of a hostile takeover bid by Mylan, said Thursday that it would reduce its workforce by approximately 800 employees, or approximately 6 percent of its current global headcount. More…
The hostile takeover bid for Perrigo Co. PLC continues with Mylan NV hosting a Tuesday, 5 pm, conference call to pitch the buyout to Perrigo shareholders. Perrigo has rejected the $27 billion buyout offer, More…
Mylan N.V. on Monday announced that it has officially took its $27 billion takeover bid directly to shareholders of Perrigo Company plc (NYSE: PRGO; TASE). In April 29th Mylan made the same offer, then More…
Trying to fend off a hostile takeover attempt by Mylan’s $27 billion bid, Perrigo Chairman, President and CEO Joseph Papa sent a letter to Mylan Executive Chairman Robert Coury to ‘clarifying More…
Mylan N.V. (NASDAQ: MYL) shareholders have approved Mylan’s proposed acquisition of Perrigo Company plc (NYSE: PRGO; TASE). The transaction received the approval of two-thirds of the votes cast at the extraordinary More…
Perrigo Company plc (NYSE: PRGO; TASE) today responded to the announcement that Mylan N.V. has lowered the acceptance condition for its proposed unsolicited offer to acquire Perrigo from not less than 80% More…
Generic pharmaceutical company Mylan N.V. (MYL) today officially announced a reduction in the approval requirement for the Perrigo Company (NYSE:PRGO; TASE:PRGO) deal from 80% to 50%. This means that under More…
